1Florida Alzheimer's Disease Research Center

佛罗里达州现在和将来都有大约56万阿尔茨海默病(AD)患者和400万65岁的居民 继续成为美国AD疫情的震中。1佛罗里达ADRC是一项合作 佛罗里达大学之间，包括佛罗里达大学(UF)，Mt.迈阿密海滩的西奈医疗中心 (MSMC)、迈阿密大学(UM)、佛罗里达国际大学(FIU)和佛罗里达大西洋大学(FAU)。 佛罗里达州ADRC的全球使命是与AD领域的其他ADRC和利益相关者合作，帮助改变 AD和相关痴呆(ADRD)对新现实的理解，在这种现实中，ADRD更容易和 诊断准确，治疗更有效，最终可预防或治愈。我们所知道的大部分 关于阿尔茨海默病的自然历史、认知衰退的风险因素以及对干预措施的反应来自于 对高加索人口的研究，主要是欧洲人的后裔。多项研究表明，更高的发病率 西班牙裔和其他代表性不足的少数群体(URM)中的痴呆症，但这些发现是否 是否具有广泛的概括性尚不清楚。我们成功招募和评估了占多数的西班牙裔队列 使我们能够开始评估拉美裔和非拉美裔之间的ADRDS是否存在差异 南佛罗里达州的西班牙裔。增进我们对不同民族和种族的痴呆症的了解 人口是我们ADRC的一个主要主题，将扩大到包括非裔美国人。当我们过渡的时候 对于一个可能作为P30资助的ADRC，我们将利用我们成功的机构和调查员 合作伙伴关系，以进一步扩大我们的招募和纵向跟踪参与者，种族，语言， 文化、遗传多样性以及与阿尔茨海默病(如血管疾病、路易体)相关的共病 痴呆症(LBD))。我们的总体目标是：1)阐明早期先兆阶段的新标记 并确定我们的种族和种族多元化参与者中下降的预测因素， 没有或有不同的合并症。这些纵向队列研究、生物标记物研究和 神经病理学研究将有助于该领域更好地了解AD、合并症和疾病异质性。 2)加强我们的机构研究环境，并提供资源，以促进)独特的培训 机会；b)职业发展；c)日益重视的抗逆转录病毒药物的创新研究 关于跨学科团队科学和先进的数据分析方法。3)提供数据、研究工具和 向广泛的利益攸关方(如NACC、NCRAD)内外(例如，NACC、NCRAD)提供生物检疫，并与其互动 我们的协作机构网络。4)提供与ADRDS相关的健康教育活动 专业人士，那些正在接受培训的人，以及非专业的社区成员，以提高知识为目标， 培养技能，建立更强大的联盟，为患者及其家人提供更好的诊断和护理 家人。

With ~560,000 Alzheimer’s disease (AD) patients and >4 million residents >65 years old, Florida is, and will continue to be, an epicenter of the AD epidemic in the United States. The 1Florida ADRC is a collaboration between Florida institutions, including the University of Florida (UF), Mt. Sinai Medical Center in Miami Beach (MSMC), University of Miami (UM), Florida International University (FIU), and Florida Atlantic University (FAU). The 1Florida ADRC’s global mission is to work with other ADRCs and stakeholders in the AD field to help change the understanding of AD and related dementias (ADRDs) to a new reality in which ADRDs are more facilely and accurately diagnosed, more effectively treated, and ultimately preventable or curable. Much of what we know about the natural history of AD, risk factors for cognitive decline, and response to interventions has come from study of Caucasian populations, largely of European descent. Multiple studies suggest a higher incidence of dementia among Hispanics and other underrepresented minority populations (URM), but whether these findings are broadly generalizable is unclear. Our successful recruitment and evaluation of a majority Hispanic cohort has enabled us to begin to evaluate whether there are differences in ADRDs between Hispanics and non- Hispanics in South Florida. Enhancing our understanding of dementia in ethnically and racially diverse populations is a major theme of our ADRC that will be expanded to include African Americans. As we transition towards an ADRC potentially funded as a P30, we will leverage our successful institutional and investigator partnerships to further expand our recruitment and longitudinal follow up of participants with ethnic, linguistic, cultural, and genetic diversity, as well as comorbidities associated with AD (e.g., vascular disease, Lewy Body Dementia (LBD)). Our overall specific aims are to: 1) Elucidate novel markers for the earliest prodromal stages of cognitive impairment and identify predictors of decline in our ethnically and racially diverse participants, who present with no or varied comorbidities. These longitudinal cohort studies, biomarker studies, and neuropathological studies will help the field to better understand AD, comorbidities, and disease heterogeneity. 2) Enhance our institutional research environments and provide resources to foster a) unique training opportunities; b) career development; and c) novel and innovative research in ADRDs with a growing emphasis on cross-disciplinary team science and advanced data analysis approaches. 3) Provide data, research tools and biospecimens to, and interact with, a wide variety of stakeholders within and outside (e.g., NACC, NCRAD) of our collaborating institutional network. 4) Provide educational activities relevant to ADRDs to health professionals, those in training, and to lay community members, with the goals of improving knowledge, developing skills, and building stronger coalitions to deliver better diagnoses and care to patients and their families.